N that have to be addressed in further studies: Considering the nanomolar affinity constant of the Zarvin:Cetuximab complex and the high concentration of various IgG antibodies in blood serum of humans (denoted IgGx) the complex could undergo rapid dissociation and subsequent Zarvin:IgGx complex formation upon application. Although this could hamper the detection of metastasis, the application of Zarvin could yet be a desired option for the detection of centres of inflammation in patients exhibiting elevated levels of specific antibodies while suffering from autoimmunic diseases or rheumatoid arthritis. A more crucial task to improve Zarvin for in vivo applications is to optimize the kinetic stability of the Zarvin:(Gd3+)2 complex by site directed mutagenesis to cage the metal ion more firmly inside the binding sites.ConclusionWe conclude that Zarvin keeps its native conformation at body temperature and is not sensitive 16574785 to protease degradation in blood serum. Due to its monomeric form and 4EGI-1 custom synthesis molecular weight Zarvin is likely to be excreted from the system by renal filtration without the need of enzymatic degradation in the blood. Zarvin’s high longitudinal relaxivities combined with its IgG binding feature make it a promising tumour candidate T1 contrast agent for targeting tumours and for the highly sensitive detection of metastases in MRI.Supporting InformationFigure S1 Molecular dynamics simulation studies of Zarvin. Left, JI-101 boxplot of the secondary structure elements over the MD simulations. Right, histogram of the distances between the Z domain and Parvalbumin. (TIF)Number of water molecules in the first coordination sphere of Ca2+ ions of S55D/E59D rat alpha-Parvalbumin in percent. The plot shows the distribution (black circles and crosses) of one (x-axis) and two (y-axis) water molecules in the first coordination shell of Ca2+ during the molecular dynamics simulations as well as the calculated averages (red circle and cross). Points with an exclusive coordination of one water in the first coordination shell (position x = 1 and y = 0)) were separated along the x-axis for better readability. (TIF)Figure S2 Figure S3 Integrity and structure of Zarvin. A, MALDI mass spectrum of Zarvin yielding a mass of 19156.1 Da (theoretical mass 19156.3 Da for M+H+). B, CD spectrum of Zarvin recorded in 20 mM Na2PO4, pH 7.4 and room temperature. C, Overlay of 1H-15N-HSQC spectra of Zarvin (green), S55D/E59D rat alpha-Parvalbumin (blue) and the Z domain (red).Modular Contrast AgentK58 is the last amino acid of the Z domain and thus shifts within Zarvin due to the Glycine10 linker, which now follows after K58. The majority of the resonances of Zarvin align nearly perfectly with those of the single domains. Thus, both domains fold independently and correctly within Zarvin. (TIF)Figure S4 Controls. Controls of the cell based experiment in which A431 cells were incubated with the complex Zarvin-D72CAtto-594:Cetuximab (Figure 1C of the main text). (TIF) Figure S5 Affinity measurements of Lanthanide ion binding. Left, titration of 3 mM TbCl3 and 8 mM Zarvin with NTA. Luminescence of Terbium (III) was recorded. The curve was normalized 23977191 and inverted prior to fitting. It was known from an active site titration that binding of Tb3+ to the EF-site (5? 6 higher Ca2+ affinity than the CD-site4) contributes to a larger amount to the overall luminescence measured (approximately 56). This effect produces a quasi-cooperative behavior of the luminescence signal upon titr.N that have to be addressed in further studies: Considering the nanomolar affinity constant of the Zarvin:Cetuximab complex and the high concentration of various IgG antibodies in blood serum of humans (denoted IgGx) the complex could undergo rapid dissociation and subsequent Zarvin:IgGx complex formation upon application. Although this could hamper the detection of metastasis, the application of Zarvin could yet be a desired option for the detection of centres of inflammation in patients exhibiting elevated levels of specific antibodies while suffering from autoimmunic diseases or rheumatoid arthritis. A more crucial task to improve Zarvin for in vivo applications is to optimize the kinetic stability of the Zarvin:(Gd3+)2 complex by site directed mutagenesis to cage the metal ion more firmly inside the binding sites.ConclusionWe conclude that Zarvin keeps its native conformation at body temperature and is not sensitive 16574785 to protease degradation in blood serum. Due to its monomeric form and molecular weight Zarvin is likely to be excreted from the system by renal filtration without the need of enzymatic degradation in the blood. Zarvin’s high longitudinal relaxivities combined with its IgG binding feature make it a promising tumour candidate T1 contrast agent for targeting tumours and for the highly sensitive detection of metastases in MRI.Supporting InformationFigure S1 Molecular dynamics simulation studies of Zarvin. Left, boxplot of the secondary structure elements over the MD simulations. Right, histogram of the distances between the Z domain and Parvalbumin. (TIF)Number of water molecules in the first coordination sphere of Ca2+ ions of S55D/E59D rat alpha-Parvalbumin in percent. The plot shows the distribution (black circles and crosses) of one (x-axis) and two (y-axis) water molecules in the first coordination shell of Ca2+ during the molecular dynamics simulations as well as the calculated averages (red circle and cross). Points with an exclusive coordination of one water in the first coordination shell (position x = 1 and y = 0)) were separated along the x-axis for better readability. (TIF)Figure S2 Figure S3 Integrity and structure of Zarvin. A, MALDI mass spectrum of Zarvin yielding a mass of 19156.1 Da (theoretical mass 19156.3 Da for M+H+). B, CD spectrum of Zarvin recorded in 20 mM Na2PO4, pH 7.4 and room temperature. C, Overlay of 1H-15N-HSQC spectra of Zarvin (green), S55D/E59D rat alpha-Parvalbumin (blue) and the Z domain (red).Modular Contrast AgentK58 is the last amino acid of the Z domain and thus shifts within Zarvin due to the Glycine10 linker, which now follows after K58. The majority of the resonances of Zarvin align nearly perfectly with those of the single domains. Thus, both domains fold independently and correctly within Zarvin. (TIF)Figure S4 Controls. Controls of the cell based experiment in which A431 cells were incubated with the complex Zarvin-D72CAtto-594:Cetuximab (Figure 1C of the main text). (TIF) Figure S5 Affinity measurements of Lanthanide ion binding. Left, titration of 3 mM TbCl3 and 8 mM Zarvin with NTA. Luminescence of Terbium (III) was recorded. The curve was normalized 23977191 and inverted prior to fitting. It was known from an active site titration that binding of Tb3+ to the EF-site (5? 6 higher Ca2+ affinity than the CD-site4) contributes to a larger amount to the overall luminescence measured (approximately 56). This effect produces a quasi-cooperative behavior of the luminescence signal upon titr.